36
Participants
Start Date
July 1, 2021
Primary Completion Date
January 12, 2023
Study Completion Date
September 22, 2023
Zotatifin
Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
Placebo
5% dextrose injection, USP
National Institute of Allergy and Infectious Diseases, Bethesda
Tampa General Hospital, Tampa
Cullman Clinical Trials, Cullman
Pinnacle Research Group, Anniston
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
Effector Therapeutics
INDUSTRY